SCHEMBL5261372

SCHEMBL5261372

NC(=O)/C(=C\c1c[nH]c2nc(NC(=O)Cc3ccc(-c4ccsc4)cc3)ccc12)c1ccc(O)c(Cl)c1

nearest known ligand 0.34

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CCNA2 P20248 3/20 0.34
CDK2 P24941 3/20 0.34
CCNA1 P78396 3/20 0.34
WNT3A P56704 3/20 0.32
RET P07949 1/20 0.32
ADORA1 P30542 2/20 0.32
GLS O94925 1/20 0.32
CHEK2 O96017 1/20 0.31
ADORA3 P0DMS8 1/20 0.31
ADORA2A P29274 1/20 0.31
ADORA2B P29275 1/20 0.31
PDK1 Q15118 1/20 0.31
NTRK1 P04629 1/20 0.30
ERN1 O75460 1/20 0.30
CYP1A2 P05177 1/20 0.30
GSK3B P49841 1/20 0.30
NPY5R Q15761 1/20 0.30
POLB P06746 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5261374 1.00 CCNA2 (0.34) CCNA2CDK2CCNA1WNT3ARET
SCHEMBL5259557 0.88 MEN1 (0.36) CCNA2CDK2CCNA1WNT3ANPY5R
SCHEMBL5259559 0.88 MEN1 (0.36) CCNA2CDK2CCNA1WNT3ANPY5R
SCHEMBL5260203 0.88 CDK2 (0.43) CCNA2CDK2CCNA1WNT3AADORA1
SCHEMBL5260205 0.88 CDK2 (0.43) CCNA2CDK2CCNA1WNT3AADORA1
SCHEMBL5259994 0.87 WNT3A (0.39) CCNA2CDK2CCNA1WNT3AADORA2A
SCHEMBL5259998 0.87 WNT3A (0.39) CCNA2CDK2CCNA1WNT3AADORA2A
SCHEMBL5259499 0.84 MEN1 (0.34) CCNA2CDK2CCNA1WNT3ANPY5R
SCHEMBL5259504 0.84 MEN1 (0.34) CCNA2CDK2CCNA1WNT3ANPY5R
SCHEMBL5263161 0.84 NPY5R (0.42) CCNA2CDK2CCNA1GLSNPY5R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1309590-B1 AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS PFIZER ITALIA SRL (IT) 2007-09-19 EP claimed
US-20030004350-A1 AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS PHARMACIA & UPJOHN (IT) 2003-01-02 US claimed
US-6335342-B1 1H-PYRROLO(2,3-B)PYRIDINE DERIVATIVES; ANTICARCINOGENIC, ANTIMETASTASIS, ANTITUMOR AND ANTIPROLIFERATIVE AGENTS PHARMACIA & UPJOHN S.P.A. (IT) 2002-01-01 US claimed
EP-1309590-B1 AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS PFIZER ITALIA SRL (IT) 2007-09-19 EP disclosed
US-20030004350-A1 AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS PHARMACIA & UPJOHN (IT) 2003-01-02 US disclosed
US-6486322-B1 Azaindole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA ITALIA S.P.A. (IT) 2002-11-26 US disclosed
US-6335342-B1 1H-PYRROLO(2,3-B)PYRIDINE DERIVATIVES; ANTICARCINOGENIC, ANTIMETASTASIS, ANTITUMOR AND ANTIPROLIFERATIVE AGENTS PHARMACIA & UPJOHN S.P.A. (IT) 2002-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030004350-A1 AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS FFAR4, AZI2, CNKSR1 CCNA2 315/4885CDK2 316/4885CCNA1 523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.